VivoSeq
Nephrology

Renal Transplant Recipients

0

Pipeline Programs↗

7

Active Trials↗

6

Companies Involved↗

Renal Transplant Recipients is an early-stage landscape with 0 programs across 6 companies. The most active players are Novartis, Pfizer, Roche.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalAstellas logo

Astellas

0 programs

PreclinicalCSL Behring logo

CSL Behring

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

98

clinical trials

Completed62 · 63%
Terminated13 · 13%
Unknown status12 · 12%
Withdrawn4 · 4%
Active, not recruiting3 · 3%
Recruiting3 · 3%
Other1 · 1%

Clinical Trials

Trial Activity

98 trials

Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs
Recruiting·—·Phase 4·NCT06268769·300 enrolled
Shingrix in Renal Transplant Recipients
Recruiting·UUniversity of Colorado, Denver·Phase 3·NCT04128189·132 enrolled
Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.
Recruiting·MMayo Clinic·Phase 4·NCT06568549·350 enrolled
A Study of TCD601 in de Novo Renal Transplant Recipients
Active, not recruiting·IITB-Med LLC·Phase 2·NCT05669001·76 enrolled
Envarsus XR® in Adolescent Renal Transplant Recipients
Active, not recruiting·UUniversity of California, Los Angeles·Phase 4·NCT03266393·28 enrolled
RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients
Active, not recruiting·UUniversity Medical Center Groningen·Phase 4·NCT03797196·374 enrolled
European Transplant Registry of Senior Renal Transplant Recipients on Advagraf
Not yet recruiting·—·N/A·NCT02558452·1,000 enrolled
Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for Renal Transplant Recipients
Completed·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT00306397·100 enrolled
Conversion of Prograf to Advagraf in Pediatric Renal Transplant Recipients
Completed·SSeoul National University Hospital·Phase 2/3·NCT01476488
24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients
Completed·Novartis logoNovartis·Phase 4·NCT01169701·71 enrolled
Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients
Completed·UUniversity Hospital Muenster·Phase 4·NCT00204321·80 enrolled
Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk
Completed·UUniversity of Oslo School of Pharmacy·Phase 4·NCT00138970·70 enrolled
ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients
Completed·Novartis logoNovartis·Phase 4·NCT00170846·394 enrolled
A Pilot Study Using Autologous Regulatory T Cell Infusion Zortress (Everolimus) in Renal Transplant Recipients
Completed·—·Phase 1·NCT03284242·9 enrolled
Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.
Completed·Novartis logoNovartis·Phase 3·NCT00238992·144 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)